Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Rocket Lab Awarded $816M Prime Contract to Build Missile- Defense Satellite Constellation for U.S. Space Force

December 19, 2025

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

December 19, 2025

Predictu Launches AI-Driven Prediction Market Platform with Leverage Trading

December 19, 2025

Remedy’s Nutrition® Launches Mega VMT™ High-Potency Multivitamin to Revolutionize Daily Energy and Nutritional Wellness

December 19, 2025

Tax season is still months away. Doing 3 things now could help you later

December 19, 2025
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » REZOLUTE INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT
Press Release

REZOLUTE INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT

By News RoomDecember 19, 20252 Mins Read
REZOLUTE INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT
Share
Facebook Twitter LinkedIn Pinterest Email
REZOLUTE INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options

If you suffered significant losses in Rezolute stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) —  Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rezolute, Inc. (“Rezolute” or the “Company”) (NASDAQ: RZLT).

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

Rezolute, Inc. shares tumbled sharply on December 11, 2025, as investors reacted to disappointing topline results from its Phase 3 sunRIZE clinical trial for ersodetug, its lead drug candidate for treating congenital hyperinsulinism. The study failed to meet both its primary and key secondary endpoints, with the highest dose showing reductions in hypoglycemia events that were not statistically significant versus placebo.

During intraday trading, RZLT collapsed from levels near its prior day close of around $10.94 to an intraday low near $0.90, representing an approximate 85–90% drop as markets opened and halted trading under Nasdaq’s volatility controls.

To learn more about the Rezolute investigation, go to www.faruqilaw.com/RZLT or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2fceea32-072d-4e7c-b9fd-7ceadbf788ad

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Rocket Lab Awarded $816M Prime Contract to Build Missile- Defense Satellite Constellation for U.S. Space Force

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Predictu Launches AI-Driven Prediction Market Platform with Leverage Trading

Remedy’s Nutrition® Launches Mega VMT™ High-Potency Multivitamin to Revolutionize Daily Energy and Nutritional Wellness

GeeFi (GEE) Shows Resilience Amid Market Pressure as Its Presale Nears $1.5M Raised in a Few Weeks

Bitget Teams Up with Google Developer Group ETH Zurich to Accelerate Web3 and AI Skills Among Students

Alli AI Unveils an Innovative System for Creating and Editing 8K Video Up to 60 Seconds Long, Rivaling Hollywood Production Quality

Kartoon Studios Celebrates 100th Anniversary of First Publication of A.A. Milne’s Winnie-The-Pooh

Galantas Gold Provides Update on Acquisition of RDL Mining Corp. and Brokered Financing

Editors Picks

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

December 19, 2025

Predictu Launches AI-Driven Prediction Market Platform with Leverage Trading

December 19, 2025

Remedy’s Nutrition® Launches Mega VMT™ High-Potency Multivitamin to Revolutionize Daily Energy and Nutritional Wellness

December 19, 2025

Tax season is still months away. Doing 3 things now could help you later

December 19, 2025

Subscribe to News

Get the latest Canada news and updates directly to your inbox.

Latest News

Bowen Yang to exit ‘Saturday Night Live’ after 8 seasons

December 19, 2025

GeeFi (GEE) Shows Resilience Amid Market Pressure as Its Presale Nears $1.5M Raised in a Few Weeks

December 19, 2025

Bitget Teams Up with Google Developer Group ETH Zurich to Accelerate Web3 and AI Skills Among Students

December 19, 2025
Facebook X (Twitter) Pinterest TikTok Instagram
© 2025 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version